Literature DB >> 35608444

Artificial Intelligence Tool for Assessment of Indeterminate Pulmonary Nodules Detected with CT.

Roger Y Kim1, Jason L Oke1, Lyndsey C Pickup1, Reginald F Munden1, Travis L Dotson1, Christina R Bellinger1, Avi Cohen1, Michael J Simoff1, Pierre P Massion1, Claire Filippini1, Fergus V Gleeson1, Anil Vachani1.   

Abstract

Background Limited data are available regarding whether computer-aided diagnosis (CAD) improves assessment of malignancy risk in indeterminate pulmonary nodules (IPNs). Purpose To evaluate the effect of an artificial intelligence-based CAD tool on clinician IPN diagnostic performance and agreement for both malignancy risk categories and management recommendations. Materials and Methods This was a retrospective multireader multicase study performed in June and July 2020 on chest CT studies of IPNs. Readers used only CT imaging data and provided an estimate of malignancy risk and a management recommendation for each case without and with CAD. The effect of CAD on average reader diagnostic performance was assessed using the Obuchowski-Rockette and Dorfman-Berbaum-Metz method to calculate estimates of area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Multirater Fleiss κ statistics were used to measure interobserver agreement for malignancy risk and management recommendations. Results A total of 300 chest CT scans of IPNs with maximal diameters of 5-30 mm (50.0% malignant) were reviewed by 12 readers (six radiologists, six pulmonologists) (patient median age, 65 years; IQR, 59-71 years; 164 [55%] men). Readers' average AUC improved from 0.82 to 0.89 with CAD (P < .001). At malignancy risk thresholds of 5% and 65%, use of CAD improved average sensitivity from 94.1% to 97.9% (P = .01) and from 52.6% to 63.1% (P < .001), respectively. Average reader specificity improved from 37.4% to 42.3% (P = .03) and from 87.3% to 89.9% (P = .05), respectively. Reader interobserver agreement improved with CAD for both the less than 5% (Fleiss κ, 0.50 vs 0.71; P < .001) and more than 65% (Fleiss κ, 0.54 vs 0.71; P < .001) malignancy risk categories. Overall reader interobserver agreement for management recommendation categories (no action, CT surveillance, diagnostic procedure) also improved with CAD (Fleiss κ, 0.44 vs 0.52; P = .001). Conclusion Use of computer-aided diagnosis improved estimation of indeterminate pulmonary nodule malignancy risk on chest CT scans and improved interobserver agreement for both risk stratification and management recommendations. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Yanagawa in this issue.

Entities:  

Mesh:

Year:  2022        PMID: 35608444      PMCID: PMC9434821          DOI: 10.1148/radiol.212182

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   29.146


  33 in total

1.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

2.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.

Authors:  Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 91.245

3.  The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules.

Authors:  S J Swensen; M D Silverstein; D M Ilstrup; C D Schleck; E S Edell
Journal:  Arch Intern Med       Date:  1997-04-28

Review 4.  Models to Estimate the Probability of Malignancy in Patients with Pulmonary Nodules.

Authors:  Humberto K Choi; Michael Ghobrial; Peter J Mazzone
Journal:  Ann Am Thorac Soc       Date:  2018-10

5.  Accuracy of clinicians and models for estimating the probability that a pulmonary nodule is malignant.

Authors:  Alex A Balekian; Gerard A Silvestri; Suzanne M Simkovich; Peter J Mestaz; Gillian D Sanders; Jamie Daniel; Jackie Porcel; Michael K Gould
Journal:  Ann Am Thorac Soc       Date:  2013-12

Review 6.  Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Michael K Gould; Jessica Donington; William R Lynch; Peter J Mazzone; David E Midthun; David P Naidich; Renda Soylemez Wiener
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

7.  Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study.

Authors:  Nichole T Tanner; Jyoti Aggarwal; Michael K Gould; Paul Kearney; Gregory Diette; Anil Vachani; Kenneth C Fang; Gerard A Silvestri
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

Review 8.  Approaches to lung nodule risk assessment: clinician intuition versus prediction models.

Authors:  Adam H Fox; Nichole T Tanner
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 2.895

9.  The Probability of Lung Cancer in Patients With Incidentally Detected Pulmonary Nodules: Clinical Characteristics and Accuracy of Prediction Models.

Authors:  Anil Vachani; Chengyi Zheng; In-Lu Amy Liu; Brian Z Huang; Thearis A Osuji; Michael K Gould
Journal:  Chest       Date:  2021-08-06       Impact factor: 9.410

Review 10.  Noninvasive biomarkers for lung cancer diagnosis, where do we stand?

Authors:  Michael N Kammer; Pierre P Massion
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.